Life Sciences - een-portugal.pt

2013

Life Sciences

2

Portugal

aicep Portugal Global

Content

Life Sciences

PORTUGAL IS A BUSINESS OPPORTUNITY

Why choose

Portugal?

Strategic location

Portugal is the European nearest country to the U.S.

3-hour distance between Brazil and Russia.

Same time as UK and Ireland.

Why choose

Portugal?

Portugal 10,6

Iberian Market 51

European Market 494

Portuguese Speaking countries 220

Attractive Consumer Market

Million Inhabitants

Great and privilege economic relations

between Portugal and Brazil, Angola and

Mozambique.

Daily flights to major European cities.

Qualified Workforce

Flexible labour lawHigh-standard educationWide availabilityPartnerships with world-class US institutions

71,7%

42% At least 1 language

23% At least 2 languages

6% At least 3 languages

43,6

Working Days Lost

(per 1.000 employees – EIRO, 2005-

2009)

11,3

Portugal has a highly skilled and educated

workforce. Portugal ranks on Top within the

EU countries in number of PhDs per 1,000

inhabitants.

40% of students in tertiary education are

enrolled in engineering, sciences and health.

The increase rate in the last 3 years is about

30%.

Portuguese are known for commitment to

work which places us below the EU average

regarding working days lost per year.

Language skills: English, French and Spanish

are the most spoken languages. English is

universally taught from 1st grade.

Why choose

Portugal?

Competitive Costs

Portugal is still cost competitive according to international recognized

sources. There was a decrease of -1,2% in hourly labour costs in 2012

Q1 (Euro 27 rose by +2,0%).

In terms of real estate – industrial space - and within 53 countries/cities

worldwide, Portugal/Lisbon is the 8th less expensive location.

Portugal also has one of the lowest monthly minimum wage in Europe

(485€).

11,4 12,4

Electricity (Prices for industries in

€/100kWh – Eurostat 2012

S1)

3,4 4,0

Natural Gas (Prices for industries, in €/GJ –

Eurostat 2012 S1)

87 100

Cost of Living (HFC 2011 - Eurostat)

+1,5

Labour Cost Index (Year-on-year rate of change –

Eurostat 2012 Q1)

-1,2

Why choose

Portugal?

1,5

Technological Infrastructures

Why choose

Portugal?

Telecommunications have been

a major priority in Portugal. The

country has now 95% coverage

of broadband infrastructures.

The net increase in the

broadband penetration growth for

Portugal is above the OECD

average (Dec 2010).

The percentage of fiber connections in total

broadband is already 6% for Portugal,

ahead of countries such as Netherlands,

Finland, France, Spain, Italy, Poland,

Austria Germany or Belgium.

The Internet is also well developed.

Portugal is a United Nations case study in

terms of e-Government and its availability

of public services on-line.

0,38 0,72

Telecom Prices Euro/10 min call

Eurostat 2010

FULLY DIGITALIZED

Office Space available

Portugal offers a dynamic real estate market. High quality

space, well designed and energy efficiency oriented has

boomed and rent prices are competitive comparing the other

European countries.

Why choose

Portugal?

Occupancy cost, in €/sqm/year, C&W2011

Industrial space

123,5

52,2 79,2

Occupancy cost, in €/sqm/year, C&W2013

Office space

915

290 439

Portugal is ahead of

countries such as France

and Spain in terms o

cost. The figures are

shown for Lisbon. If we

considered Porto area,

prices can lower 25%.

The Technological parks spread all

over the country offer excellent

conditions to establish operations

in manufacturing, retail, services

or research. Major parks are

close to Universities or higher

education institutions and have

good roadway accessibilities.

Services offered:

• Meeting and conference rooms;

• Auditoriums;

• Education centers;

• Incubating facilities;

• Labs;

• Financial services;

• Private funding;

• Researchers from Universities;

• Parking area, restaurants, etc.

High-Tech Parks

Business friendly environment

Why choose

Portugal?

MULTI-CULTURAL

Portugal is very open to foreign cultures:

the availability of international schools,

the safety record and quality of life

attract expatriates.

As a result Portugal is ranked #2 in the

Migrant Integration Policy Index 2011.

“Portugal is unique in attracting young

graduates and executives.” Carlos

Brazão, Cisco Portugal

EASE OF DOING BUSINESS

• Major public services are on-line;

• Portugal is considered by the United

Nations, a case study in e-

Government;

• Average time to set up a firm is less

than 1-hour

They chose us

Why choose

Portugal?

Our decision is a result of the recognition of the hospitality and

the commitment of the Portuguese Government, of the multilingual skills of the

local population as well as its professionalism and ability, and proven success

in innovation areas.”

Chris Dedicoat, Senior Vice-President for Europe, Cisco

“

”

One of our main strategic lines was always to shorten

distances with the academic world and to bet in strong innovation,

investigation and development in Portugal thus taking advantage of the

Portuguese engineer’s excellence.

João Picoto, Chairman of Nokia Siemens Networks

Portugal

“

”

SERVICES MANUFACTURING

Life Sciences:

An Overview

Source: Health Cluster Portugal, 2011

OVERVIEW The Health Cluster in Portugal: an eco-system

Pharma & Biotech

Medical Devices

Healthcare

R&D Centers

Universities

/Education

Technological parks

Shared Services

Retail

Manufacturing

Services

IT

Regulatory Bodies Infarmed, Ministry of Health

CORE ACTIVITIES

Life Sciences in Portugal

• Turnover: 319 Million Euro

• Employment: 4,573

• Number of companies: 985

• Gross Value Added: 125 Million Euro

• Exports 2011: 209 Million Euro


Pharma

Source: INE 2013, SCIE, Figures for 2011

CORE ACTIVITIES

• Turnover: 1,181 Million Euro

• Employment: 6,196

• Number of companies: 133

• Gross Value Added: 346 Million

Euro



The Health Cluster in Portugal: an eco-system OVERVIEW

Medical Devices

Healthcare

• Turnover: 11,211 Million Euro

• Total Employment: 247,630

• Number of companies: 82,303

• Gross Value Added: 5,028 Million Euro

• Increasing rate in the last 5 years: +24.3%

Industry sector

with relevant

weight in

employment and

value added.


PhDs in Portugal, by year (2001=100)

Investing in HR has been a major priority HR

247

212

50

100

150

200

250

2001 2002 2003 2004 2005 2006 2007 2008 2009 2010

PhD

s in P

ort

ugal 2001=

100

Health TOTAL

The allocation of scientific area is based on the Classification of Fields of Science - 2007 (FOS) in the English translation of the "Revised Classification of Fields

of Science and Techonology» Frascati Manual 2002, version May 2006.

Source: Statistical survey to the National Register of Themes PhD Thesis in Progress and Completed PhD Higher Education, GPEARI / MEC, DGEEC, 2011


2

4

6

8

10

2001 2003 2005 2007 2008 2009 2010 2011p

‰ a

ctive p

opula

tion

R&D - Human Ressources

Total RH Researchers

Source: Aicep

Champalimaud Foundation, a private

biomedical research center which aims to

support researchers working at the

cutting-edge of medical science. A special

focus on neuroscience research,

translational cancer research, and clinical

practice.

More at: www.fchampalimaud.org

International Iberian Nanotechnology

Laboratory is the first fully international

research organization in Europe in the

field of nanoscience, nanomedicine and

nanotechnology, with at least 200

researchers and 100 PhD students from

all over the world.

More at: www.inl.int/

R&D

Portugal hosts several recently- created world class R&D institutions of excellence.


Source: APBio

R&D

Portugal hosts several world class R&D institutions of excellence.

AIBILI - Association for Innovation and Biomedical Research on Light and Image

is a private non-profit organisation, founded in 1989, established to support technology

transfer to industry. AIBILI is dedicated to help the development of new products for

pharmaceutical and biotechnology companies, with special expertise in Ophthalmology.

BIOCANT is an applied research and development center that provides innovative

services of Biotechnology relevant to Life Sciences and promotes the development of

R&D in consortium with national and international companies to the creation of new

products and services. The Centre drives technology transfer between fundamental

research centres of known competence and biotech companies.

BIOCANT is the R&D centre of BIOCANT PARK, the first Portuguese technology park

dedicated to Biotechnology.

CNC - Center for Neuroscience and Cell Biology is a non-profit biomedical research

center at the University of Coimbra. CNC brings together scientists from the Faculties of

Science and Technology, Medicine and Pharmacy and from the University Hospital.

The CNC is structurally subdivided in ten departments (Cell Biology, Biophysics,

Biochemistry, Neurochemistry, Neuropharmacology, Molecular Biotechnology,

Neurobiology, Microbiology, Vectors and Gene Therapy, Graduate Studies and Advanced

Strategic Studies), each headed by a director, and the Laboratory of NMR.


Source: IBMC and APBIO

R&D


IBMC – Institute for Molecular and Cell Biology is a multidisciplinary research institution

that was formed in 1997 with the aim of bringing together researchers working within the

University of Porto and affiliated hospitals to produce a unique environment promoting

research in the life sciences.

IGC - Instituto Gulbenkian de Ciência’s scientific interests are focused on the genetic

basis of development and evolution of complex systems, privileging organism-centred

approaches in experimental models that include plants, yeast, flies and mice, and on the

genetics of complex human diseases. A strong theoretical sector (Estudos Avançados de

Oeiras) is one of the Institute’s specificities, the others being the quality of the services, and

a strong investment on international exchange in the form of graduate courses, workshops

and symposia.

IMM - Instituto de Medicina Molecular is a Non-profit Association, whose associate members are

the University of Lisbon, the University of Lisbon School of Medicine, the Santa Maria Hospital, the

Portuguese Institute of Oncology, the University of Lisbon Foundation, the Association for Research

and Development of the University of Lisbon Medical School, and the Oriente Foundation.

An important added value derives from the close interactions between IMM, the medical school and

the University hospital. These entities established a consortium to promote translational research by

providing a framework to develop pre-clinical research, clinical research and new technologies,

which is excellently positioned to disseminate new discoveries to university education, to the biotech

and pharmaceutical industry, and to medical practitioners


Source: APBIO

R&D


INEB - Instituto de Engenharia Biomédica, has four working Groups:

The Biointerface Group focus on the tissue-material interface, at cellular levels.

The Bioceramics and Glasses Group focus on the research to the development of novel synthetic bone

grafts for the treatment of clinical situations associated with bone trauma, bone disease and ageing.

The Biomedical Imaging and Vision Computing Group addresses the Image Analysis in Medicine and

Biology program and the Vision Computing and Biomedical Modelling.

The Signal Processing Group unites researchers in signals and systems engineering and clinical

monitoring.

IPATIMUP - Institute of Molecular Pathology and Immunology main goals are: research in human

pathology, with particular emphasis on oncobiology; training of graduate students, technicians,

residents and specialists in pathology; diffusion of scientific knowledge and teaching of undergraduate

students; providing sophisticated diagnostic expertise in the different fields covered by the Institute:

pathology, oncobiology and population genetics

ITQB - Instituto de Tecnologia Química e Biológica is a research institute of the Universidade Nova

de Lisboa. Its mission is to provide advanced training in an interdisciplinary environment through high

quality research work in Chemistry, Biology and associated technologies.

Since 2001, ITQB together with Instituto Gulbenkian de Ciência and Instituto de Biologia Experimental

e Tecnológica (IBET) constitutes an Associate Laboratory


PORTO UNIVERSITY

NOVA

UNIVERSITY

LISBON UNIVERSITY

MINHO UNIVERSITY

COIMBRA UNIVERSITY

ALGARVE UNIVERSITY

CATHOLIC UNIVERSITY

EDUCATION

Main Portuguese Universities with undergraduate

programs and R&D Institutions in Sciences & Health

AVEIRO UNIVERSITY

BEIRA INTERIOR UNIVERSITY

ÉVORA UNIVERSITY

TRÁS-OS-MONTES/ ALTO DOURO UNIVERSITY

INSTITUTO SUPERIOR TÉCNICO


Source: Aicep

In 2009, an International Cooperation

Program was launched between Medical

Schools in Portugal and the U.S. Harvard

Medical School to foster collaborative

clinical research in areas related to

human disease, and launch post-

graduate medical training.

MIT Portugal has launched the

Bioengineering Systems, a world-class

graduate program offered jointly by four

Portuguese universities focused in

physical, chemical and biological

engineering, computational systems, and

medical technologies.

Prestigious academic Institutions have chosen Portugal for partnerships on cutting

edge research and education.

EDUCATION


Source: http://www.fraunhofer.pt

EDUCATION

Prestigious academic Institutions have chosen Portugal for partnerships on cutting

edge research and education.

Fraunhofer Portugal in Oporto coordinates cooperation

between research institutes in Portugal with the

Fraunhofer Institutes in Germany and manges the

Fraunhofer Research Center for Assistive Information

and Communication Solutions in conjunction with the

University of Porto.


http://www.fraunhofer.pt/

Did you know?

Several Portuguese

scientists have been

awarded by Gates

Foundation for outstanding

work in Malaria.

[November 11, 2010]

In 2012 round of Howard

Hughes Medical Institute

Grants, five out 28 grants

were awarded to

Portuguese scientists.

Major foreign companies also chose Portugal

PLAYERS


http://www.syngenta-us.com/

http://www.talecris.com/talecris-biotherapeutics-home.htm

BIAL, Portuguese largest pharmaceutical company, invests

20% of its revenues in R&D for new medicines. The company

has 6 new worldwide patented molecules and sells its

medication in more than 30 countries. Main areas are:

musculoskeletal system, central nervous system,

cardiovascular diseases, antibiotic therapy, respiratory

diseases, immunotherapy.

BIAL

LATEST NEWS

BIAL Foundation has the goal to encourage the scientific study

of the human being. Through the BIAL award and grants, BIAL

has analyzed 518 projects and mobilized 1,156 researchers and

has distinguished 227 authors .

MAIN PLAYERS


Labesfal is the biggest manufacturer of medicines for

hospital use and market leader in several products. Its

state of the art facilities at Santiago de Besteiros,

integrating 4 production units in 3 independent buildings

with floor area of more than 38.000 m2

Since 2005 Labesfal is 100% subsidiary of Fresenius Kabi.

Fresenius Kabi provides: Infusion Therapy, Parenteral

Nutrition, Enteral Nutrition, Infusion Technology,

Transfusion Technology and Ambulatory Care.

LABESFAL – FRESENIUS KANI MAIN PLAYERS

FAST FACTS

Revenues: €128.5

Mn (2012)

Jobs: 500

Exports: 67%

40 destination

countries

For the second time Labesfal was distinguished in 2011

as “the Best Pharmaceutical Company” by the

Portuguese magazine “Exame”.


http://www.google.pt/url?sa=i&source=images&cd=&cad=rja&docid=u2ISi0b5_iQQNM&tbnid=3or3F7R8451_fM:&ved=0CAgQjRwwAA&url=http%3A%2F%2Fwww.fresenius.de%2Flogos&ei=ytJmUdnNFsjPhAfHjYCwCg&psig=AFQjCNHCxtWb7ADsJkTemHTy_iIHIdrTow&ust=1365779530401142

Hovione is an international group dedicated to the cGMP

development and manufacture of APIs, serving exclusively

the pharmaceutical industry. With FDA inspected plants in

Europe, the Far East and the US, Hovione has a 50-year

track record committed to the highest levels of service and

quality.

HOVIONE MAIN PLAYERS

FAST FACTS

Revenues: US$

180 Mn (2011)

Jobs: 1,100

Nº of sites: 5

(China, Portugal,

Ireland, USA)


ATRAL-CIPAN and CGC GENETICS MAIN PLAYERS

AtralCipan is a Portuguese leader pharmaceutical group in the

development, scale-up, manufacturing and commercialisation of

Active Pharmaceutical Ingredients (API) and Finished Dosage

Forms (FDF).

AtralCipan develops an integrated marketing activity, for the

national and international markets, granting its presence in several

health areas, including veterinary, otc and parapharmacy products

CGC Genetics has been the

leading provider of specialty

genetic tests in Portugal and has

grown into one of Europe’s major

clinical laboratories. The

company offers more than 1,500

genetic tests covering all major

medical disciplines including

prenatal screening and

diagnosis, hematology, oncology,

neurology, cardiology, preventive

medicine, common and rare

diseases and pharmacogenetics.

LATEST NEWS


“50 years experience in industrial fermentation

capacity over 850 000 liters”

Software & Pharmaceutical MAIN PLAYERS

ALERT is a comprehensive suite for healthcare software

solutions from the point of care to the patient’s home and

everything between, including EMR, HIE, PHR, BI and

CRM. With 8 sites across the world, software is available

in major languages, thus enabling to target almost any

major market. For instance, the length of triage process

can be reduced up to 70%.

BLUEPHARMA, a FDA certified company is a

Portuguese Pharmaceutical based in Coimbra. It

produces pharmaceutical drugs and generics and has

a strong investment in Research, Development and

registration of pharmaceutical drugs.

In 2010 it wan the International Quality Award, a

distinction granted internationally by the several

chambers of commerce and embassies. Bluepharma's

strong investment in R&D was recognized by the

National Ranking for Scientific and Technologic

Potential, promoted by the Ministry of Science and

Technology, which places it in 2nd place among all

pharmaceutical companies.


http://www.alert-online.com/pt

http://www.bluepharma.pt/

http://farm6.static.flickr.com/5221/5571177834_ce6f51609d.jpg

Medical Devices MAIN PLAYERS

Fapomed is dedicated to the

production of single use

medical devices, such as

surgical gowns, surgical

covers, drapes and CPT

(Custom Procedure Trays)

either sterile and non- sterile.

Fapomed employs around

200 people and has 2

factories in Portugal and it

has recently opened a

factory in Ukraine.

Fapomed®, Steribata®,

Sterikit®, Accuro®,

Cirgikit®, Safetray® are

international registered

trade marks owned

by Fapomed, SA.

Bastos Viegas is the main Portuguese producer and

supplier of Non Active Medical Devices. The

company products are in over 80 countries

distributed by the 6 continents.

In parallel, it represents

in Portugal many

international brands of

Medical Devices for the

wholesale distribution in

the national market.

The retail distribution is

made under the

registered brands

Medical Express and

Bel Express, in whose

catalogues there are

more than 10.000

references.


Pharmaceutical MAIN PLAYERS

Grupo Azevedos is among

the most solid

pharmaceutical groups in

Portugal. The company

offers contract

manufacturing, licensing-

out OTC products,

distribution agreements for

innovative prescription

and OTC products and

regulatory and

promotional services.

Grupo Azevedos

employs around 600

people, an annual

turnover of 140 M€ and

production and

distribution sites in 20

locations around the

world.

Tecnimede Group is a key player in

Generic Medicines. It develops new

pharmaceutical forms, including modified

release forms and sterile forms,

production of oral solid pharmaceutical

forms and scaling-up, validation of

processes. •Employment: 542

•Turnover: 100 M€

•Exports: 20%

•R&D Expenses: 15% sales


http://www.google.pt/url?sa=i&rct=j&q=tecnimede&source=images&cd=&cad=rja&docid=J1y-WOZ27V-TLM&tbnid=rqB-DVumR2PNaM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.rcmpharma.com%2Factualidade%2Findustria-farmaceutica%2F13-01-12%2Fgrupo-tecnimede-cresce-43-em-exportacoes-em-2011&ei=MXVmUZCwCYXJ0QWc1YCgDQ&bvm=bv.45107431,d.ZG4&psig=AFQjCNH1-_CAMtXoFTrJS-37Ox3P0p4BQg&ust=1365755564141701

Fresenius Kabi Group (Labesfal unit) recently announced a new

investment project for adopting new technologies applied to production,

logistic and distribution. It also allows the company to introduce new

products such as EAS, Quetiapina e Montelukas. The project amounts to 8

M€, creates 27 new jobs and retains the existing 469.

Recently, three R&D projects were announced by the company intended

to research new therapies for epilepsy, neuropathic pain (new

Eslicarbazepine acetate solutions) and Parkinson disease.

Total Investment: 130M€

New jobs: 43

Retained jobs: 250

Recent Investment Track Record


http://www.google.pt/url?sa=i&source=images&cd=&cad=rja&docid=u2ISi0b5_iQQNM&tbnid=3or3F7R8451_fM:&ved=0CAgQjRwwAA&url=http%3A%2F%2Fwww.fresenius.de%2Flogos&ei=ytJmUdnNFsjPhAfHjYCwCg&psig=AFQjCNHCxtWb7ADsJkTemHTy_iIHIdrTow&ust=1365779530401142

We are a Business Development Agency, focused on

the development of a competitive business

environment that contributes to the international

expansion of the Portuguese Economy.

Who are we?

Increasing the country’s competitiveness,

promoting large private investment and fostering

the internationalization of Portuguese companies. Mission

Values

Focus on clients. We serve our clients in accordance to their requirements

through various solutions and long-term relationships.

Selectiveness. We direct our activity towards projects and markets that

make a better contribution to company competitiveness and the

sustainability of the Portuguese economy.

Excellence. We seek to exceed expectations by means of a rigorous

approach, effectiveness, enthusiasm and a willingness to innovate.


About Us

aicep Portugal Global: how can we help

you?

1

Pre- Investment

2

Incentives

Negotiation

3

Settling In

4

After Care

Promoting a direct negotiation

with companies, through which a

tailored approach to incentives

may be applied in order to define

a global package that fully

satisfies the investor's needs

Single point of contact

in all phases: pre-

investment, incentives

negotiation, settling in

and after care

Government

business entity,

flexible, free of

charges and

streamlined services

Dynamic

approach

focused on the

client or investor

www.portugalglobal.pt

Life Sciences - een-portugal.pt

Documents

Transcript of Life Sciences - een-portugal.pt